4-[4-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]phenyl]but-3-yn-1-ol | 299461-26-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[4-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]phenyl]but-3-yn-1-ol
• CAS: 299461-26-0
• 化学式: C₂₉H₃₁ClN₂O₂
• 分子量: 475.03
• InChiKey: GPOROFHFJYPJQK-GDLZYMKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  35.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[4-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]phenyl]but-3-yn-1-ol 在 偶氮二甲酸二异丙酯 、 氨 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-{4-[4-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)phenyl]but-3-yn-1-yl}-1-hydroxyurea
  参考文献：
  名称：

  Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity

  摘要：

  A series of compounds possessing both H, histamine receptor antagonist and 5-lipoxygenase (5-LO) inhibitory activities was synthesized. The H-1-binding scaffolds of cetirizine, efletirizine, and loratadine were linked to a lipophilic N-hydroxyurea, the 5-LO inhibiting moiety of zileuton. Both activities were observed in vivo, as was increased CYP3A4 inhibition compared to their respective single-function drugs. Selected analogs in the series were shown to be orally active in guinea pig models. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.060
• 作为产物：
  描述：

  1-(2-溴乙氧基)-4-碘苯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[4-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]phenyl]but-3-yn-1-ol
  参考文献：
  名称：

  Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity

  摘要：

  A series of compounds possessing both H, histamine receptor antagonist and 5-lipoxygenase (5-LO) inhibitory activities was synthesized. The H-1-binding scaffolds of cetirizine, efletirizine, and loratadine were linked to a lipophilic N-hydroxyurea, the 5-LO inhibiting moiety of zileuton. Both activities were observed in vivo, as was increased CYP3A4 inhibition compared to their respective single-function drugs. Selected analogs in the series were shown to be orally active in guinea pig models. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.060

文献信息

• Compounds and methods for treatment of asthma, allergy and inflammatory disorders
  申请人：UCB S.A.

  公开号：US20030220347A1

  公开（公告）日：2003-11-27

  The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.

  本发明提供了1,4-取代哌嗪、1,4-取代哌啶和1-取代、4-烷基亚烯基哌啶化合物。本发明的化合物是具有白三烯抑制性和抗组胺性的双重作用分子。本发明的化合物用于治疗可能存在组胺和/或白三烯成分的病症。这些病症包括哮喘、季节性和全年性过敏性鼻炎、鼻窦炎、结膜炎、食物过敏、鲭鱼中毒、牛皮癣、荨麻疹、瘙痒、湿疹、类风湿性关节炎、炎症性肠病、慢性阻塞性肺疾病、血栓性疾病和中耳炎。还提供了通过向需要治疗哮喘和鼻炎的受试者施用有效的缓解哮喘和鼻炎的化合物量的方法。
• 凝血カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換された４−ピロン類
  申请人：ファルマシア・コーポレーション

  公开号：JP2004505014A

  公开（公告）日：2004-02-19

  本発明は、凝血カスケードのセリンプロテアーゼの阻害剤として有用な多環式アリールおよびヘテロアリール置換された４−ピロン化合物；および、冠状動脈および脳血管疾患を含め、多種多様な血栓状態を治療および予防するための抗凝血治療用の化合物、組成物および方法に係る。

  多环芳基和杂芳基取代的 4-吡喃酮化合物，可用作凝血级联中丝氨酸蛋白酶的抑制剂；以及用于抗凝治疗的化合物、组合物和方法，以治疗和预防各种血栓性疾病，包括冠心病和脑血管疾病。与化合物和方法有关。
• POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE
  申请人：Pharmacia Corporation

  公开号：EP1268463A2

  公开（公告）日：2003-01-02
• US6451801B1
  申请人：——

  公开号：US6451801B1

  公开（公告）日：2002-09-17
• US6686502B1
  申请人：——

  公开号：US6686502B1

  公开（公告）日：2004-02-03